Lead Product(s) : Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka Announces Phase 3 Results of AVP-786 for Agitation Associated with Alzheimer’s
Details : AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) is a combinational a CYP2D6 inhibitor. It is being evaluated for the treatment of dementia due to Alzheimer’s disease.
Product Name : AVP-786
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai Submits Rolling BLA for Leqembi® Subcutaneous Maintenance Dosing in the US
Details : Leqembi (lecanemab) is an IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for the treatment of Alzheimer’s disease.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
October 31, 2024
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mitsubishi Tanabe Presents Data from Phase 3 BouNDless Trial of ND0612 in Parkinson's
Details : ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.
Product Name : ND0612
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Eisai’s LEQEMBI® Supplemental Application for Early Alzheimer’s Treatment
Details : Leqembi (lecanemab), a humanized IgG1 monoclonal antibody directed against aggregated soluble & insoluble forms of amyloid-beta. It is being evaluated for the treatment of early alzheimer’s disease.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
July 06, 2024
Lead Product(s) : Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka to Terminate Development of AVP-786
Details : Termination of development of the novel compound AVP-786 (deudextromethorphan HBr), in development for the treatment of agitation associated with dementia due to Alzheimer's.
Product Name : AVP-786
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai Initiates Rolling BLA for LEQEMBI® for Alzheimer’s Disease Maintenance Dosing
Details : Leqembi (lecanemab-irmb) is a humanized IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for Alzheimer’s disease.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
May 14, 2024
Submission Of Leqembi® sBLA for IV Maintenance Dosing Completed
Details : Leqembi (lecanemab-irmb) is a humanized IgG1 monoclonal antibody targeting amyloid-beta, being evaluated for IV maintenance dosing in early Alzheimer's disease treatment.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
March 31, 2024
Lead Product(s) : Methylcobalamin
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai Submits NDA in Japan for Ultrahigh-Dose Mecobalamin to Treat ALS
Details : Methycobal (methylcobalamin) is the active form of vitamin B12. It is indicated for the treatment of peripheral neuropathies and megaloblastic anemia caused by vitamin B12 deficiency.
Product Name : E0302
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 26, 2024
Lead Product(s) : Methylcobalamin
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyqvia [Immune Globulin Infusion 10% (Human) is a liquid medicine containing Recombinant Human Hyaluronidase & immunoglobulins (Ig) & is approved by EMA as a replacement therapy in adults, children & adolescents with primary immunodeficiency & with secon...
Product Name : Hyqvia
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 15, 2023
Details : Hyqvia is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins (Ig). It is being evaluated in phase 3 clinical trials in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Product Name : Hyqvia
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 15, 2023